Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 plus chemotherapy in first-line advanced NSCLC
CTR20202437Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Dec 2020
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in non-small cell lung cancer (NSCLC), sponsored by Akeso, Inc.. Started Dec 2020; status: completed.
02
Drugs
cadonilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20202437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202437.